|
X-ray Targeted Therapeutic Genes within Nanoparticles
|
1R01CA125757-01A1
|
$364,320
|
$364,320
|
Hallahan, Dennis
|
VANDERBILT UNIVERSITY
|
|
WUMC-Cancer and Leukemia Group B
|
5U10CA077440-10
|
$334,381
|
$23,407
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Virotherapy for Relapsed Refractory Multiple Myeloma
|
5R01CA125614-02
|
$246,400
|
$123,200
|
DISPENZIERI, ANGELA
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Viral Vectors in Tumors: Effects of Taxol and Radiation
|
5R01CA098706-05
|
$268,835
|
$67,209
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Viral Proteins: Gene Delivery to Specific Malignancies
|
5R01CA081171-07
|
$249,183
|
$249,183
|
ALBRITTON, LORRAINE
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
|
5R01CA079218-08
|
$328,425
|
$65,685
|
GILL, PARKASH
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
VCU Minority-Based CCOP
|
3U10CA052784-17S1
|
$100,000
|
$1,000
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based CCOP
|
5U10CA052784-17
|
$527,332
|
$5,273
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Validation of a New Target for Prostate Cancer Therapy
|
5R01CA102688-04
|
$289,700
|
$144,850
|
BARON, VERONIQUE
|
SIDNEY KIMMEL CANCER CENTER
|
|
UTMDACC SPORE in Breast Cancer
|
3P50CA116199-03S1
|
$398,581
|
$99,645
|
HORTOBAGYI, GABRIEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UTMDACC SPORE in Breast Cancer
|
5P50CA116199-03
|
$2,180,817
|
$545,204
|
HORTOBAGYI, GABRIEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
USING VIRAL NANOPARTICLES TO TARGET CANCER
|
5R01CA112075-03
|
$726,519
|
$363,260
|
MANCHESTER, MARIANNE
|
SCRIPPS RESEARCH INSTITUTE
|
|
Use of Adjuvants to Improve Skin Genetic Immunizations
|
5R01CA100893-04
|
$256,389
|
$25,639
|
LARREGINA, ADRIANA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras
|
5R01CA073756-09
|
$249,182
|
$249,182
|
BALDWIN JR, ALBERT
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-08
|
$2,249,522
|
$899,809
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Iowa CALGB Institutional Grant
|
5U10CA047642-20
|
$119,291
|
$8,350
|
VAENA, DANIEL
|
UNIVERSITY OF IOWA
|
|
Ultraviolet-Induced Signal Trasduction
|
5R01CA077646-08
|
$236,453
|
$35,468
|
DONG, ZIGANG
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
1R21CA116127-01A1
|
$202,499
|
$202,499
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis
|
5R01CA118085-02
|
$290,571
|
$72,643
|
ZHOU, PENGBO
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Tumor-Targeting Oligonucleotides
|
5R01CA122383-02
|
$255,082
|
$63,771
|
BATES, PAULA
|
UNIVERSITY OF LOUISVILLE
|
|
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors
|
5R01CA121830-02
|
$258,587
|
$258,587
|
Xu, Liang
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Tumor targeted RNAi by novel nanovectors for molecular therapy of prostate cancer
|
1R21CA128220-01
|
$97,280
|
$97,280
|
Xu, Liang
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Tumor Sensitization to Purine Analogs by E. coli PNP
|
5R01CA119170-02
|
$309,985
|
$309,985
|
SORSCHER, Eric
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Tumor Hypoxia Imaging - Laboratory and Clinical Studies
|
5P01CA115675-02
|
$1,870,179
|
$467,545
|
LING, CLIFTON
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor
|
1R01CA116322-01A2
|
$257,013
|
$257,013
|
JI, LIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Triple Anti-Angiogenic Therapy for Brain Tumors
|
5R01CA083127-07
|
$190,620
|
$95,310
|
Yung, W K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Treatment of Malignant Gliomas with 2-5A-anti-hTR
|
5R01CA108558-04
|
$293,510
|
$293,510
|
BOGLER, OLIVER
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Transposon Mediated Gene Therapy for Colorectal Cancer
|
1R01CA120383-01A1
|
$309,901
|
$309,901
|
McIvor, R
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Translational Applications of mda-7/IL-24 in Cancer
|
5P01CA104177-03
|
$1,235,688
|
$617,844
|
FISHER, PAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Transgenic Mice as Models for Antivascular Therapy
|
5R01CA099519-05
|
$334,388
|
$117,036
|
LEE, WILLIAM
|
UNIVERSITY OF PENNSYLVANIA
|
|
Transformation of Cells by the REL Oncogene
|
5R01CA047763-20
|
$275,637
|
$27,564
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
Transfer of the CD40 ligand gene to esophageal carcinoma
|
5R01CA101982-05
|
$357,594
|
$357,594
|
KORST, ROBERT
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Transduction of T-cells to improve migration to tumor
|
5R01CA116206-03
|
$282,772
|
$197,940
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
TRAIL-induced apoptosis in prostate cancer
|
5R01CA102218-04
|
$249,182
|
$124,591
|
VOELKEL-JOHNSON, CHRISTINA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Toward a transcription therapy for breast cancer
|
5R01CA113682-02
|
$268,871
|
$268,871
|
MUYAN, MESUT
|
UNIVERSITY OF ROCHESTER
|
|
Tissue Specific Gene Therapy for Human Prostate Cancer
|
5R01CA074042-10
|
$265,033
|
$265,033
|
Kao, Chinghai
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
TIMP-2-mediated Tumor Cell Differentiation and Chemo-sensitization Therapy
|
Z01 BC 010829
|
$421,555
|
$210,777
|
Stetler-Stevenson, William
|
CCR (NCI)
|
|
THERAPY OF CML
|
5P01CA049639-19
|
$3,552,240
|
$710,448
|
CHAMPLIN, RICHARD
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Therapeutic Manipulation of the B7-like Molecules
|
5R01CA098731-06
|
$310,442
|
$155,221
|
Chen, Lieping
|
JOHNS HOPKINS UNIVERSITY
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-08
|
$1,891,032
|
$472,758
|
HERSCHMAN, HARVEY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
THE THERAPY OF AML
|
2P01CA055164-15A1
|
$2,404,845
|
$120,242
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Small DNA Tumor Virus Conference
|
5R13CA083239-09
|
$14,223
|
$2,133
|
LAMBERT, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
The role of p53 in remodeling DNA methylation in cancer
|
5R01CA106630-04
|
$244,189
|
$24,419
|
TAYLOR, SHIRLEY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
The role of JNK in Mammary tumor development
|
5R01CA100238-05
|
$278,349
|
$27,835
|
VAN DEN BERG, CARLA
|
UNIVERSITY OF TEXAS AUSTIN
|
|
The Role of Artemis in Cellular Responses to DNA Damage
|
5R01CA096574-04
|
$293,511
|
$29,351
|
LEGERSKI, RANDY
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Regulation of UPA and UPAR in Human Carcinoma Cells
|
7R01CA093926-06
|
$232,488
|
$58,122
|
HUANG, SHUANG
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
The Apoptogenic Role of p53 at the Mitochondria
|
5R01CA060664-13
|
$264,543
|
$132,272
|
MOLL, UTE
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
The Adenovirus Receptor CAR in Epithelial Malignancies
|
5R01CA095701-05
|
$255,696
|
$255,696
|
Korn, Wolfgang
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
TGF-Beta Suppression and Promotion of Mammary Carcinomas
|
5R01CA085492-07
|
$436,193
|
$143,944
|
MOSES, HAROLD
|
VANDERBILT UNIVERSITY
|
|
TGF Beta receptor biology in human renal cell carcinoma
|
5R01CA104505-04
|
$230,760
|
$115,380
|
COPLAND, JOHN
|
MAYO CLINIC COLL OF MED, JACKSONVILLE
|
Total relevant funding to Gene Therapy for this search: $86,063,332
|